Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# UCLTF

Investing in innovation

## Sitemaps

- [XML Sitemap](https://ucltf.co.uk/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Inside Albion Ventures' decade-long partnership with UCL](https://ucltf.co.uk/inside-albion-ventures-decade-long-partnership-with-ucl/) - Why do so few university spinouts successfully make the journey from lab to market? In this episode of Lab to Market Leadership, Chris explores this vital question with Dave Grimm, Partner at Albion Ventures, who has spent the last decade revolutionising the spinout process through a unique partnership with University College London. Dave reveals how
- [UK has world-class IP, talent and ideas - so the time for bold, foundational investment is now](https://ucltf.co.uk/uk-has-world-class-ip-talent-and-ideas-so-the-time-for-bold-foundational-investment-is-now/)
- [UCL Spinout Stanhope AI raises £2.3 million](https://ucltf.co.uk/ucl-spinout-stanhope-ai-raises-2-3-million/) - Stanhope AI - the world’s first company applying decades of neuroscience research to teach machines how to make human-like decisions in the real world – has successfully raised £2.3 million in seed funding led by the UCL Technology Fund. Creator Fund also participated, along with, MMC Ventures, Moonfire Ventures and Rockmount Capital and leading angel
- [Oriole Networks raises a £10m seed round to build AI ‘super-brains’](https://ucltf.co.uk/oriole-networks-raises-10m-in-seed-funding-to-build-ai-super-brains-capable-of-training-llms-100x-faster-with-a-fraction-of-energy/) - Oriole Networks – the startup using light to train LLMs a hundred times faster with only a fraction of power – has raised £10 million in Seed funding to revolutionise AI performance and adoption, and solve AI’s critical energy problem. The round, which is one of the UK’s largest Seed raises in recent years, was
- [EpilepsyGTx announces a $10M fundraise to complete the CTA-enabling nonclinical package for lead program EPY201](https://ucltf.co.uk/epilepsygtx-announces-a-10m-fundraise-to-complete-the-cta-enabling-nonclinical-package-for-lead-program-epy201/) - EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy, today announced it has raised a total of $10 million in seed funding. The financing was led by the UCL Technology Fund, with participation from Health Technology Holding. The funds raised will be used to complete the
- [Gaussion raises $12m to revolutionize battery charging](https://ucltf.co.uk/gaussion-raises-12m-to-revolutionize-battery-charging/) - Charging speed remains a significant hurdle to overcome in the mass market adoption of passenger and commercial electric vehicles (EVs). Rapid charging under traditional electrochemistry is inherently unpredictable, often dangerously damaging cells and next-generation technologies such as solid-state electrolytes have repeatedly fallen short of deployment targets. Gaussion, a University College London (UCL) spinout, has developed
- [EpilepsyGTx raises $33m Series A to develop single dose gene therapy for focal refractory epilepsy](https://ucltf.co.uk/epilepsygtx-raises-33m-series-a-to-develop-single-dose-gene-therapy-for-focal-refractory-epilepsy/) - EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical
- [Early trigger of diabetic eye disease identified](https://ucltf.co.uk/early-trigger-of-diabetic-eye-disease-identified/) - Exciting news from UCL scientists, who have identified a key protein that triggers diabetic retinopathy, a leading cause of blindness among working-age adults. The breakthrough could shift treatment from managing late-stage damage to preventing vision loss altogether. Senya Therapeutics co-founders Prof. John Greenwood and Prof. Stephen Moss together with a team at the UCL Institute
- [Phasecraft raises $34M to bring quantum computing closer to real-world impact](https://ucltf.co.uk/phasecraft-raises-34m-to-bring-quantum-computing-closer-to-real-world-impact/) - Phasecraft, the world’s leading quantum algorithms company, today announced it has raised $34 million in Series B funding to accelerate its breakthrough work to transform quantum computing’s theoretical promise into practical applications. Co-led by Plural, existing investor Playground Global, and Novo Holdings’ Quantum Fund in its first direct quantum software investment, the round also included
- [Breakthrough gene therapy transforms teenager's life](https://ucltf.co.uk/breakthrough-gene-therapy-transforms-teenagers-life/) - A major milestone in gene therapy has been reached at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (UCL GOSH ICH), where the first-ever clinical trial for patients with p47 Chronic Granulomatous Disease (CGD) is underway. The rare genetic immunodeficiency affects about one in a million people and leaves patients vulnerable to severe
- [Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study](https://ucltf.co.uk/tenpoint-therapeutics-announces-positive-topline-data-from-phase-3-pivotal-study/) - Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL™ PF for the Treatment of Presbyopia BRIMOCHOL™ PF, successfully met the pre-specified visual acuity primary endpoints for both the US and EU/UK with highly statistically significant near vision improvements over 8 hours, paving the way for US filing in 1H, 2025
- [Tenpoint Therapeutics & Visus Therapeutics, Inc. join forces building the next era of Best-and First-in-Class ophthalmic medicines](https://ucltf.co.uk/tenpoint-therapeutics-visus-therapeutics-inc-join-forces-building-the-next-era-of-best-and-first-in-class-ophthalmic-medicines/) - Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce todaythe completion of their merger to create an entirely new chapter in ophthalmic therapeuticmedicines aimed at rejuvenating the aging eye. The merger brings together a late-stage,potentially best-in-class, presbyopia-correcting eye drop, BRIMOCHOL™ PF, on track forNDA filing in 1H, 2025, with a promising pipeline of innovative therapeutics.The
- [New immunotherapy from UCL researchers to treat bone cancer shows promise](https://ucltf.co.uk/new-immunotherapy-from-ucl-researchers-to-treat-bone-cancer-shows-promise/) - A new type of immunotherapy, developed by UCL researchers, has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice. Osteosarcoma is the most common bone cancer in teenagers but is still relatively rare, with around 160 new cases each year in the UK. Meanwhile, more than 150,000
- [AstronauTx appoints Jane Rhodes as Chief Executive Officer](https://ucltf.co.uk/astronautx-appoints-jane-rhodes-as-chief-executive-officer/) - London UK, 01 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotech company backed by UCLTF developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA as Chief Executive Officer (CEO) and member of the Board. Jane is an accomplished leader with 25 years of experience
- [UCL spinout tackling eye disease announces £57m launch](https://ucltf.co.uk/ucl-spinout-tackling-eye-disease-announces-57m-launch/) - Tenpoint Therapeutics, which spun out of UCL in 2021, has announced its launch with £57m of funding, to address degenerative eye diseases. The biotechnology company uses pioneering cell engineering to replace damaged cells in the eye to tackle age-related or inherited sight loss. The technology could potentially restore sight to millions affected. Tenpoint Therapeutics was
- [Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca](https://ucltf.co.uk/quell-therapeutics-signs-a-collaboration-exclusive-option-and-license-agreement-with-astrazeneca-to-develop-manufacture-and-commercialise-engineered-treg-cell-therapies-for-autoimmune-diseases/) - Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialise autologous, engineered Treg cell therapies for two autoimmune disease indications. Quell combines
- [Hazy raises $9m to power synthetic data usage in enterprises](https://ucltf.co.uk/hazy-raises-9m-to-power-synthetic-data-usage-in-enterprises/) - Leading synthetic data disruptor, Hazy, announced today that it has raised $9 million in Series A funding. The investment is led by Conviction, with participation from UCL Technology Fund, M12 (Microsoft), Wells Fargo, Nationwide Building Society, ACT Venture Partners, Terra VC, Evenlode, Logo Ventures, Sarus Ventures and Neva SGR, the Intesa Sanpaolo bank venture capital
- [Intrinsic Semiconductor Technologies Secures £7m Investment](https://ucltf.co.uk/intrinsic-semiconductor-technologies-secures-7m-investment/) - Intrinsic Semiconductor Technologies, the next generation memory technology company, today announced it has secured £7 million in a funding round led by Octopus Ventures and supported by existing investors IP Group and the UCL Technology Fund as well as £1m in InnovateUK grants. The new funding will support the expansion of its engineering team to
- [Orchard Therapeutics announces strategic financing totalling up to $188m](https://ucltf.co.uk/orchard-therapeutics-announces-strategic-financing-totalling-up-to-188m/) - UCLTF portfolio company Orchard Therapeutics has announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants that could bring in up to $188 million. The financing was led by RA Capital Management and attracted new and existing investors Deep Track Capital, Cowen Healthcare Investments, Woodline Partners LP
- [First heart patients diagnosed using technology developed by Echopoint - Financial Times](https://ucltf.co.uk/first-heart-patients-diagnosed-using-echopoint-financial-times/) - The iKOr device, a new fibre optic technology developed at Barts Health and UCL, has begun clinical testing on patients to find out the causes of heart disease. The device has a temperature and pressure sensor that is 0.2mm wide which is threaded through the patient’s blood vessels. It measures the flow rate around the
- [Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development](https://ucltf.co.uk/apollo-tx-and-institute-of-cancer-research-enter-into-collaboration/) - ICR joins UCL, University of Cambridge, Imperial College London and King’s College London as a strategic partner; Apollo continues focus on accessing the world’s best science. Apollo Therapeutics (‘Apollo’), a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, announce they have
- [Carbon Re raises £4.2m seed funding to tackle gigatonnes of emissions from the highly pollutive cement industry](https://ucltf.co.uk/carbon-re-raises-4-2m-seed-funding-to-tackle-gigatonnes-of-emissions/) - UCLTF portfolio company, Carbon Re, has raised £4.2 million seed funding to scale up development and deployment of its novel technology. Carbon Re, a climate tech company building state-of-the-art AI to decarbonize energy-intensive industries, has raised £4.2 million seed funding to scale up development and deployment of its novel technology. Their Delta Zero AI platform
- [Oriole Networks raises a further $22m led by Plural to reduce energy consumption of AI data centres](https://ucltf.co.uk/oriole-networks-raises-a-further-22m-led-by-plural-to-reduce-energy-consumption-of-ai-data-centres/) - Oriole Networks - the company using light to train Large Language Models with a fraction of the usual AI energy consumption - has raised an additional $22 million from leading investors to further scale its “super-brain” solution. The round was led by Plural with all existing investors – UCL Technology Fund, XTX Ventures, Clean Growth Fund, and
- [MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease](https://ucltf.co.uk/meiragtx-announces-positive-data-from-randomized-sham-controlled-clinical-bridging-study-ofaav-gad-for-the-treatment-of-parkinsons-disease/) - MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced top-line data from its clinical bridging study of AAV-GAD for the treatment of Parkinson’s disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its commercial platform process. Participants
- [Cancer Research UK and NovalGen collaborate to advance T-cell engager into the clinic](https://ucltf.co.uk/cancer-research-uk-and-novalgen-collaborate-to-advance-t-cell-engager-into-the-clinic/) - Cancer Research UK, one of the world’s largest funders of cancer research, and NovalGen, a pioneering clinical stage immunology company, have signed an agreement to bring NovalGen’s next-generation T-cell engager, NVG-222, into a first-in-human clinical trial. Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will sponsor, design and deliver a Phase 1/2a
- [Founder Stories University Edition with Professor Amit Nathwani, CEO NovalGen](https://ucltf.co.uk/founder-stories-university-edition-with-professor-amit-nathwani-ceo-novalgen/) - In this episode Professor Amit Nathwani, CEO of NovalGen and a leading global mind in gene therapy research, walks UCLTF's Simon Goldman, through his academic and business career and what still drives him today.
- [Founder Stories University Edition with Ashley Montanaro, CEO & Co-founder Phasecraft](https://ucltf.co.uk/founder-stories-university-edition-with-ashley-montanaro-ceo-co-founder-phasecraft/) - Professor Ashley Montanaro, co-founder of Phasecraft, chats to David Grimm, AlbionVC partner, about the world of quantum science and Phasecraft’s leading role in that space.
- [Founder Stories University Edition with Professor Tony Kenyon, CSO & Co-founder Intrinsic](https://ucltf.co.uk/founder-stories-university-edition-with-professor-tony-kenyon-cso-co-founder-intrinsic/) - Professor Tony Kenyon, Intrinsic CSO & Co-founder, chats to David Grimm, AlbionVC partner, about the company’s journey to revolutionise the semiconductor industry. Further information: Discover more about Intrinsic.
- [COP28: Carbon Re's Buffy Price talks AI and carbon savings](https://ucltf.co.uk/cop28-carbon-res-buffy-price-talks-ai-and-carbon-savings/) - With the COP28 climate talks taking place in Dubai, many people are wondering what solutions are available right now that could help have a real impact on global emissions. We took the opportunity to talk to Buffy Price, Interim CEO and Co-founder of Carbon Re, a growing business created from research at UCL’s Energy Institute,
- [Orchard Therapeutics presents additional positive data regarding MPS-IH ](https://ucltf.co.uk/orchard-therapeutics-presents-additional-positive-data-regarding-mps-ih/) - Orchard Therapeutics has presented additional positive data from a proof-of-concept study of OTL-203 in MPS-IH at the European Society of Gene and Cell Therapy (ETSG) 2023. The gene therapy company announced a range of interim clinical outcomes, in addition to the previously reported neurological and skeletal results, from its ongoing proof-of-concept (PoC) study of OTL-203,
- [Apollo Therapeutics closes second Series C financing, bringing the round’s total to $260m](https://ucltf.co.uk/apollo-therapeutics-closes-second-series-c-financing-bringing-the-rounds-total-to-260m/) - UCLTF portfolio company Apollo Therapeutics has revealed that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5m: bringing the total raised in this round by the company during 2023 to $260m. The Series C financing was led by Patient Square Capital and included participation by multiple new
- [UCL Spinout Echopoint Medical Ltd Secures £4.2 Million in Series A Funding, Advancing FDA Approval Process for iKOr System](https://ucltf.co.uk/ucl-spinout-echopoint-medical-ltd-secures-4-2-million-in-series-a-funding-advancing-fda-approval-process-for-ikor-system/) - Echopoint Medical, an innovative force in cardiovascular diagnostic technology and a spinout from UCL, announces a £4.2 million in Series A funding. This investment will support the company's flagship iKOr system through the FDA approval process, setting the stage for its market debut in the United States. Echopoint Medical is committed to revolutionizing the field
- [UCLTF tips its hat to the next generation of women and girls in science](https://ucltf.co.uk/ucltf-tips-its-hat-to-the-next-generation-of-women-and-girls-in-science/) - In celebration of International Day of Women and Girls in Science, we hear from two members of the UCLTF team, Leigh Brody and Sara Watson to find out what makes their roles unique and what led them towards a career in bioscience investment. Taking place on Sunday 11th February, International Day of Women and Girls
- [New Alzheimer’s hope as UCL spinout AstronauTx closes $61m Series A financing](https://ucltf.co.uk/new-alzheimers-hope-as-uclb-spinout-astronautx-closes-61m-series-a-financing/) - AstronauTx, a biotech company spun out from UCL, developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms, has closed a $61m (£48m) Series A funding. AstronauTx was created by the Dementia Discovery Fund in 2019, with additional seed stage funding from the UCL Technology Fund and the UK Future
- [New hope for Niemann-Pick Disease Type C treatment as Bloomsbury Genetic Therapies receives Orphan Drug Designations](https://ucltf.co.uk/new-hope-for-niemann-pick-disease-type-c-treatment-as-bloomsbury-genetic-therapies-receives-orphan-drug-designations/) - UCL spinout Bloomsbury Genetic Therapies Limited has received Orphan Drug Designations (ODD) from the US Food and Drug Administration (FDA) and the European Commission (EC) for BGT-NPC, an investigational gene therapy for the treatment of Niemann-Pick Disease Type C (NPC). The clinical-stage biotechnology company is developing potentially curative treatments for patients suffering from rare neurological
- [Treatment for infantile neuroaxonal dystrophy a step closer as Bloomsbury Genetic Therapies receives Orphan Drug Designations  ](https://ucltf.co.uk/treatment-for-infantile-neuroaxonal-dystrophy-a-step-closer-as-bloomsbury-genetic-therapies-receives-orphan-drug-designations/) - UCL spinout Bloomsbury Genetic Therapies Limited has received Orphan Drug Designations (ODD) from the US Food and Drug Administration (FDA) and the European Commission (EC) for BGT-INAD, an investigational gene therapy for the treatment of Infantile Neuroaxonal Dystrophy (INAD). The clinical-stage biotechnology company is developing potentially curative treatments for patients suffering from rare neurological and
- [Investor Q&A: Barny Cox](https://ucltf.co.uk/investor-qa-barny-cox/) - UCLTF Investment manager, Barny Cox tells us what led him to his current role at UCLTF, on secondment from UCL Business. What inspired you to enter the tech transfer field as opposed to other traditional science routes? My interest in tech transfer stems from my love of life science, developed through undergraduate, postgraduate and postdoctoral
- [UCL backed tumour-busting cancer therapy cleared for clinical trials](https://ucltf.co.uk/ucl-backed-tumour-busting-cancer-therapy-cleared-for-clinical-trials/) - A tumour-busting drug developed at UCL in London, which scientists say could improve the current “dismal outlook” for people with pancreatic cancer, is set to be trialled in patients following U.S regulatory approval. Pancreatic cancer is one of the most lethal forms of cancer, with a five-year survival rate of less than 8%, according to
- [Phasecraft raises £13m, led by Playground Global, to become the first to reach practical quantum advantage](https://ucltf.co.uk/phasecraft-raises-13m-led-by-playground-global-to-become-the-first-to-reach-practical-quantum-advantage/) - Phasecraft, formed from research teams at UCL and the University of Bristol, has taken an important step in its mission to accelerate the practical quantum advantage from decades to years away, after raising a £13m Series A funding round led by Silicon Valley deeptech VC, Playground Global. AlbionVC also joined the round along with participation
- [UCL partner Apollo Therapeutics receives $226.5m to translate medical research into treatments](https://ucltf.co.uk/ucl-partner-apollo-therapeutics-receives-226-5m-to-translate-medical-research-into-treatments/) - Apollo Therapeutics, a unique collaboration between UCL, Imperial College and the University of Cambridge, and three global pharmaceutical companies, has today (6 September) announced the close of $226.5m in a Series C financing. This significantly adds to the $195m previously raised by the Company. The financing round, led by Patient Square Capital, saw the inclusion
- [The Times names UCL University of the Year 2024](https://ucltf.co.uk/the-times-names-ucl-university-of-the-year-2024/) - The Times and Sunday Times' The Good University Guide has named UCL as University of the Year 2024. The publication acknowledged UCL’s world-leading performance in multidisciplinary research and education, the career prospects of UCL’s graduates, along with the university's ambitious work around sustainability. It also highlighted UCL's new and 'visionary' UCL East Campus on Queen
- [Bramble Energy reveals world’s ‘lowest cost’ hydrogen fuel cell](https://ucltf.co.uk/bramble-energy-reveals-worlds-lowest-cost-hydrogen-fuel-cell/) - Bramble Energy, which emerged from two of Europe’s leading academic institutions, UCL and Imperial, has released a whitepaper revealing its solution to achieving a game-changing $100 per kilowatt fuel cell stack. Currently, fuel cell costs remain a major barrier to mass hydrogen adoption. Bramble, however, estimates that its stack cost would be ten-times lower than
- [UCL spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m](https://ucltf.co.uk/uclb-spinout-orchard-therapeutics-to-be-acquired-by-kyowa-kirin-for-477m/) - Orchard Therapeutics, a gene therapy company developing and commercialising medicines for rare diseases, is set to be acquired by Japanese pharmaceutical firm Kyowa Kirin for $477.6m, with a focus on creating new drugs. Orchard Therapeutics’ technology harnesses a patient’s own genetically modified hematopoietic stem cells (HSCs) to potentially correct the underlying cause of a genetic
- [Bloomsbury Genetic Therapies Receives Rare Pediatric Disease Designation from the U.S. FDA for BGT-INAD for the Treatment of Infantile Neuroaxonal Dystrophy (INAD) and Announces Upcoming Type B Pre-IND Meeting with the U.S. FDA](https://ucltf.co.uk/bloomsbury-genetic-therapies-receives-rare-pediatric-disease-designation-from-the-u-s-fda-for-bgt-inad-for-the-treatment-of-infantile-neuroaxonal-dystrophy-inad-and-announces-upcoming-type-b-pre-in/) - Bloomsbury Genetic Therapies Limited, a UCLTF portfolio company, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for BGT-INAD, the Company’s investigational gene therapy for the treatment of INAD. The FDA has also granted the Company a Type B Pre-IND meeting to be held in October to discuss
- [Bloomsbury Genetic Therapies Receives Orphan Drug Designation from the U.S. FDA for BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)](https://ucltf.co.uk/bloomsbury-genetic-therapies-receives-orphan-drug-designation-from-the-u-s-fda-for-bgt-otcd-for-the-treatment-of-ornithine-transcarbamylase-deficiency-otcd/) - Bloomsbury Genetic Therapies Limited, a UCLTF portfolio company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BGT-OTCD, the Company’s investigational liver-targeted gene therapy for the treatment of OTCD. In May, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the clinical trial application submitted by
- [Bloomsbury Genetic Therapies gets Rare Pediatric Disease designation from the US FDA for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)](https://ucltf.co.uk/bloomsbury-genetic-therapies-gets-rare-pediatric-disease-designation-from-the-us-fda-for-the-treatment-of-ornithine-transcarbamylase-deficiency-otcd/) - UCL spinout Bloomsbury Genetic Therapies Limited has been granted Rare Pediatric Disease Designation (RPDD) for BGT-OTCD, the company’s investigational liver-targeted gene therapy for the treatment of OTCD, by the US Food and Drug Administration (FDA). In May, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved the clinical trial application submitted by Bloomsbury’s collaborators
- [Bloomsbury GTx announces publication of article highlighting preclinical data from BGT-NPC programme.](https://ucltf.co.uk/bloomsbury-gtx-announces-publication-of-article-highlighting-preclinical-data-from-bgt-npc-programme/) - Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, has announced that an article highlighting first preclinical data from BGT-NPC, as a potential new brain-targeted therapeutic for the treatment of Niemann-Pick Type C Disease (NPC), was
- [Fast-charging battery startup Gaussion powers up with backing from BGF and UCL Technology Fund](https://ucltf.co.uk/fast-charging-battery-startup-gaussion-powers-up-with-backing-from-bgf-and-ucl-technology-fund/) - Gaussion, a UCL spinout that has developed new technology to allow ultrafast and safe battery charging, has raised £2.85 million in a seed investment round led by BGF and UCL Technology Fund (UCLTF). “The electrification of transport will be a big part of society’s journey towards a low carbon economy. That journey must be accomplished
- [Bloomsbury Genetic Therapies announces Orphan Drug Designations of BGT-DTDS for the treatment of Dopamine Transporter Deficiency Syndrome](https://ucltf.co.uk/bloomsbury-genetic-therapies-announces-orphan-drug-administration/) - Bloomsbury Genetic Therapies, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, has announced that both the United States Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for BGT-DTDS, the company’s neuron-targeted
- [Odin Vision acquired by Olympus](https://ucltf.co.uk/odin-vision-acquired-by-olympus/) - Odin Vision, a UCL spinout company that develops AI-driven endoscopy technology to help better detect cancer, has been acquired by Olympus Corporation (Olympus) for up to £66 million. Odin is a world-leading pioneer of cloud AI-enabled applications for endoscopy, that enables clinicians to detect some early stage colorectal and oesophageal cancers. The acquisition deal will see
- [Bloomsbury Genetic Therapies launches with Seed financing of £5m to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases](https://ucltf.co.uk/bloomsbury-gtx-launches-with-seed-financing-of-5m/) - Bloomsbury Genetic Therapies Limited, a biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, has announced its launch with £5 million Seed financing led by UCL Technology Fund. Bloomsbury’s innovative approach is designed to optimise therapeutic efficacy and safety, enable high manufacturability,
- [Investor Q&A: Leigh Brody](https://ucltf.co.uk/investor-q-and-a-leigh-brody/) - UCLTF Investor, Leigh Brody, tells us what led her to her current role at UCLTF and what she enjoys about working in investment and venture capital. What led you to working on the Life Sciences Team at UCLTF? My first encounter with the venture capital world was when I raised money to start a company
- [Orchard Therapeutics' new life-saving gene therapy to treat MLD | BBC News](https://ucltf.co.uk/orchard-therapeutics-new-life-saving-gene-therapy-to-treat-mld-bbc-news/) - Working with mission driven founders that strive to change the world drives our team at UCLTF. Orchard Therapeutics, originally a UCL spinout and now a NASDQ listed company, has developed a life-saving gene therapy drug now available on the NHS to treat patients affected by MLD, which severely damages the brain and nervous system. Orchard CEO and co-founder, Bobby Gaspar, has
- [Freeline announces the closing of sale of its CMC-focused German subsidiary](https://ucltf.co.uk/freeline-announces-the-closing-of-sale-of-its-cmc-focused-german-subsidiary/) - Freeline Therapeutics has announced the closing of the previously announced sale of its CMC-focused German subsidiary, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd. Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. The company is dedicated to improving patient lives through innovative, one-time treatments
- [World Cancer Day 2023 - Q&A with Amit Nathwani](https://ucltf.co.uk/world-cancer-day-2023-qa-amit-nathwani/) - In celebration of World Cancer Day, NovalGen Founder and CEO, Amit Nathwani, shares his insights about the company's motivations for their work in cancer and treatments for patients. What inspires you in your work on cancer treatments? The key inspiration for our work in cancer is the fact that there is still a huge unmet need
- [Freeline publishes preclinical proof of concept data for FLT190, its AAV gene therapy candidate for Fabry disease, in the Nature Journal Gene Therapy](https://ucltf.co.uk/freeline-publishes-preclinical-proof-of-concept-data/) - Freeline Therapeutics has announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a debilitating genetic disorder in which an enzyme deficiency leads to a harmful build-up of fat in the cells that causes progressive organ damage and can result
- [Q&A with Mark Dickinson, CEO, Intrinsic](https://ucltf.co.uk/qa-with-mark-dickinson-ceo-intrinsic/) - Intrinsic, the memory innovators using Resistive Random Access Memory (RRAM) technology, provide an insight about the company's journey in our latest Q&A featuring CEO, Mark Dickinson. How did Intrinsic’s journey begin, and where is it today? Intrinsic was born from many years of research by the academic founders in the area of ‘memristors’, a nanotechnology that
- [Bloomsbury GTX presents new Preclinical Data on CNS Programs at the European Society of Gene & Cell Therapy (“ESGCT”) Congress 2022](https://ucltf.co.uk/bloomsbury-gtx-presents-new-preclinical-data/)
- [Business Insider: Bramble named among the 23 startups inventing moonshot technology that are set to take off](https://ucltf.co.uk/business-insider-bramble-named-among-the-23-startups/)
- [NovalGen appoints Dr Michael Owen and Mr Scott Clarke to the Board of Directors](https://ucltf.co.uk/novalgen-new-board-directors/) - London, United Kingdom, January 9, 2023 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clarke as Non-Executive Directors to its Board, effective January 2023. “Both Mike and Scott are highly experienced industry executives who bring a wealth
- [UCL Technology Fund Showcase 2022](https://ucltf.co.uk/ucltf-showcase-2022/) - The UCL Technology Fund (UCLTF) Showcase 2022 was held on Wednesday 11th May at the British Museum. UCLTF’s event, sponsored by Google for Startups, brought together UCL academics, spinouts, investors, and the broader technology ecosystem, as presentations from the Fund’s portfolio companies and projects were delivered in person for the first time since the beginning
- [Carbon Re and Materials Processing Institute join forces for ground-breaking use of Artificial Intelligence to decarbonise steel](https://ucltf.co.uk/carbon-re-and-materials-processing-institute-join-forces/) - Carbon Re, an AI and climate tech start-up spun out of UCL, and the University of Cambridge, is partnering with the Middlesbrough-based Materials Processing Institute – the UK’s leading materials and industrial decarbonisation research organisation – to adapt Carbon Re’s state-of-the-art AI technology to steelmaking. Carbon Re announced on Tuesday 28th June its collaboration with the
- [Global University Venturing - 10 spinouts to watch: November 2022](https://ucltf.co.uk/10-spinouts-to-watch-november-2022/)
- [Quell Therapeutics awarded Best Emerging Biotech Company - OBN Awards 2022](https://ucltf.co.uk/quell-therapeutics-awarded-best-emerging-biotech-company-obn-awards-2022/)
- [UCLTF Webinar: The state of early-stage Climate Tech investing](https://ucltf.co.uk/ucltf-webinar-the-state-of-early-stage-climate-tech-investing/) - Our webinar, 'The state of early-stage Climate Tech investing' offered a fascinating insight into Climate Tech investments, startups, and Net Zero strategy. Our host, UCLTF Investment Director, David Grimm, was joined by: Aidan O'Sullivan, CTO and Co-Founder of Carbon Re, a UCLTF portfolio company who help energy-intensive industries reduce their carbon emissions. Dennis Atkinson, Investor
- [Achilles Therapeutics presents encouraging Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma](https://ucltf.co.uk/achilles-tx-presents-encouraging-phase-i-iia-update-on-clonal-neoantigen-reactive-t-cells-in-advanced-nsclc-and-melanoma/) - Achilles Therapeutics, a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumours, presented a Phase I/IIa update on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma, at
- [Vodafone Group partners with Hazy to roll out synthetic data](https://ucltf.co.uk/vodafone-group-partners-with-hazy-to-roll-out-synthetic-data/) - LONDON, 14 Dec 2022 – Leading global synthetic data firm, Hazy, announced today that it has been successfully collaborating with Vodafone to test the use of synthetic data. Synthetic data created with Artificial Intelligence (AI) from actual datasets helps companies in executing data science projects through the ability to easily share datasets across countries and
- [NovalGen announces one oral and two poster presentations at the American Society of Haematology Annual Meeting](https://ucltf.co.uk/novalgen-announces-one-oral-and-two-poster-presentations-at-the-american-society-of-haematology-annual-meeting/) - NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside an auto-regulation platform, has announced the online publication of three abstracts submitted to the American Society of Haematology Annual meeting, to be held December 10-13, 2022. Read the full story from NovalGen here.
- [MeiraGTx’s industry-leading gene therapy manufacturing facility in Shannon, Ireland formally introduced by Head of Irish Government](https://ucltf.co.uk/meiragtxs-gene-therapy-manufacturing-facility-formally-introduced-by-head-of-irish-government/) - MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, unveiled its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance. The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale gene therapy manufacturing site in Ireland. The
- [Meet Sebastian Hunte, UCLTF Investor](https://ucltf.co.uk/meet-sebastian-hunte-ucltf-investor/) - Meet UCLTF's newest Investor, Sebastian Hunte, and find out about his career in investment and technology transfer. What's your background in, and what brought you to the world of technology transfer? I did my undergraduate degree in Cognitive Science at McGill University, which was split between Computer Science and Neuroscience. During that time, I had
- [Humanloop completes $2.6m seed funding round](https://ucltf.co.uk/humanloop-completes-2-6m-seed-funding-round/) - UCLTF portfolio company, Humanloop, completed a $2.6 million (£2.1 million) seed funding round led by Index Ventures, with participation by Y Combinator, LocalGlobe, and AlbionVC. The University College AI spinout claims to make it “significantly” easier for companies to adopt a new wave of NLP technology via a suite of tools which helps humans ‘teach’ AI algorithms.
- [Freeline Therapeutics could reduce bleeding risk for haemophilia patients](https://ucltf.co.uk/freeline-tx-could-reduce-bleeding-risk-for-haemophilia-patients/) - For the paper, published in the New England Journal of Medicine, experts from UCL, Royal Free Hospital and biotechnology company Freeline Therapeutics trialled and continue to evaluate a new type of adeno-associated virus (AAV) gene therapy candidate, called FLT180a, to treat severe and moderately severe cases of the condition. The Phase I/II trial was sponsored
- [KIT-AR announces €2m in seed stage funding round](https://ucltf.co.uk/kit-ar-announces-2m-in-seed-stage-funding-round/) - KIT-AR, the augmented worker platform for the manufacturing industry, announced the completion of a €2 million seed stage funding round. This investment was co-led by Armilar Venture Partners and Caixa Capital Risc, with participation from RKKVC and Techtree fund (managed by Iberis Semper), including the follow-on investment from Sintef Venture V and Best Horizon. This
- [NovalGen announces compelling data from the Phase 1/2 Study of NVG-111](https://ucltf.co.uk/novalgen-announces-compelling-data-from-the-phase-1-2-study-of-nvg-111/) - A major breakthrough for NovalGen, announcing first clinical data from the ongoing Phase 1/2 study of NVG-111 in patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. London, United Kingdom, May 26, 2022 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announces first clinical data from the ongoing Phase 1/2 study of
- [Investor Q&A: Simon Goldman](https://ucltf.co.uk/investor-q-and-a-simon-goldman/) - UCLTF Investor, Simon Goldman tells us what led him to his current role at UCLTF and what he enjoys about working in technology transfer and investment. What led you to working on the Life Sciences Team at UCLTF? I've always enjoyed working at the nexus of cutting-edge science and finance. My undergrad was a combined
- [International Women's Day 2022](https://ucltf.co.uk/international-womens-day-2022/) - In celebration of International Women's Day, four women who work with UCLTF - Anne Lane (CEO, UCL Business), Pauline Stasiak (Investor, UCLTF), Buffy Price (Co-Founder, CarbonRe), Leigh Brody (Investor, UCLTF) - shared their insights into working in the technology transfer and investment space, and how we can encourage more women to get involved. What's the
- [Epsilogen announces completion of oversubscribed £30.75m Series B finacing](https://ucltf.co.uk/epsilogen-announces-completion-of-oversubscribed-30-75m-series-b-finacing/) - Epsilogen Ltd., a global leader in the development of novel immunoglobin E (IgE) antibodies to treat cancer, announced it has secured £30.75 million in an oversubscribed Series B financing round. The round was led by new investor Novartis Venture Fund and joined by new investors 3B Future Health Fund and British Patient Capital, Schroders Capital
- [We're hurtling towards a computing impasse - the investments we make now will define our future](https://ucltf.co.uk/were-hurtling-towards-a-computing-impasse/) - UCLTF Physical Science Investment Director, David Grimm, and Intrinsic's CTO, Adnan Mehonic discuss the future of investing in computing. It will come as no surprise that computing power is in demand, and increasingly so. From the 1960s up until around 2012, this demand was following the chip advancements made by Moore's law, doubling roughly every
- [Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet?](https://ucltf.co.uk/bringing-immuno-oncology-cell-therapies-to-the-masses/) - Scientists and clinicians within the immuno-oncology field have spent the last three decades demonstrating the remarkable potential of a whole suite of novel cell therapies that might one day cure patients of previously untreatable and deadly malignancies. However, as is the case with many other paradigm-shifting technologies, it has been a long and bumpy road
- [Bramble Energy secures £35m to fund its game changing technology to support net zero mission](https://ucltf.co.uk/bramble-secures-35m-to-fund-its-game-changing-technology-to-support-net-zero-mission/) - London-based fuel cell company Bramble Energy has closed a £35million investment round to help further expand its game changing capabilities in solving key challenges in the production and implementation of hydrogen fuel cell stacks. This investment has been led by HydrogenOne Capital Growth plc and is supported by the existing institutional investors (BGF, IP Group, Parkwalk Advisors and the UCL Technology
- [Meet Pauline Stasiak, UCLTF Investor](https://ucltf.co.uk/meet-pauline-stasiak-ucltf-investor/) - Meet UCLTF's newest Investor, Pauline Stasiak, and find out about her career in investment and technology transfer. What's your background in, and what brought you to the world of technology transfer? I'd always been interested in disease and doing something where I could help make an impact, so I started with a Microbiology degree at
- [G-quadruplex licence showcases the UCLTF’s unique commercialisation model](https://ucltf.co.uk/g-quadruplex-licence-showcases-the-ucltfs-unique-commercialisation-model/) - UCLTF Investment Director, Simon Goldman discusses UCLTF's commercialisation model, in light of the recent announcement from Qualigen Therapeutics. We’re super pleased by last week’s announcement from Qualigen Therapeutics (NASDAQ:QLGN), that they’ve licensed a small-molecule G-quadruplex stabiliser technology developed at the UCL School of Pharmacy for ongoing translation to clinic in pancreatic cancer. This program was funded in
- [Qualigen Therapeutics secures worldwide rights to G4-selective transcription inhibitors from UCL to develop as cancer therapeutics](https://ucltf.co.uk/qualigen-tx-secures-worldwide-rights-to-g4-selective-transcription-inhibitors-from-ucl/) - Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, has announced the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, which was developed by Professor Stephen Neidle and his team from the UCL School of Pharmacy.
- [MedNous interviews Professor Amit Nathwani](https://ucltf.co.uk/mednous-interviews-professor-amit-nathwani/) - MedNous recently interviewed Professor Amit Nathwani, Chief Executive Officer of UCLTF portfolio company NovalGen. He shares his views for their article, ‘Bispecific antibody development gains momentum’. Read the article here: MedNous: published in the March 2021 edition of MedNous, a publication of Evernow Publishing Ltd.
- [UCLTF's Fund Managers share their trend predictions for 2022](https://ucltf.co.uk/ucltfs-fund-managers-share-their-trend-predictions-for-2022/) - UCLTF's Fund Managers have shared their trend predictions for 2022, looking at which areas they think will see the most growth and investment. David Grimm, Investment Director We made a very safe bet by saying we wouldn’t see huge leaps forward in quantum hardware last year, and whilst there were some very exciting enabling developments
- [The rise of deeptech investments speak to an industry brimming with possibility](https://ucltf.co.uk/the-rise-of-deeptech-investments-speak-to-an-industry-brimming-with-possibility/) - UCLTF's David Grimm and Tanel Ozdemir share their insights on the deeptech industry and its bright future. The combined value of European-founded deeptech companies now exceeds $845B, and counting. Since 2010, the percentage of European venture capital being funnelled into deeptech companies has more than doubled, and 2020 saw investments into the sector surpass €10B.
- [Investor Q&A: Tanel Ozdemir](https://ucltf.co.uk/investor-q-and-a-tanel-ozdemir/) - UCLTF Investor, Tanel Ozdemir shares his thoughts on investing, and life as an academic. What led you to working on the Life Sciences Team at UCLTF? After a degree in Human Biology at King’s College London, I joined UCL for a Masters in Nanotechnology and Regenerative Medicine. During that year up at the Royal Free
- [Quell Therapeutics raises $156m in oversubscribed Series B financing](https://ucltf.co.uk/quell-tx-raises-156-million-in-oversubscribed-series-b-financing/) - UCLTF portfolio company, Quell Therapeutics raises $156 million in oversubscribed Series B financing to advance its pioneering multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform. Quell is harnessing the full power of Tregs, known as the “master modulators” of immune homeostasis, to create novel cell therapies designed to suppress overactive immune responses, drive
- [David Grimm talks to Startup Dads podcast](https://ucltf.co.uk/david-grimm-talks-to-startup-dads-podcast/) - David Grimm, UCLTF Investment Director, shares his experiences with podcast Startup Dads. He discusses how to be an empathetic investor, and why we should encourage curiosity in our kids and co-workers. Listen to his interview with Startup Dads here.
- [A Window to the Past: Is the Biotech Investment Boom Going to Last?](https://ucltf.co.uk/a-window-to-the-past/) - The biotech industry has been going through a period of fast growth in recent years. To uncover whether the current biotech investment boom will last, let’s look at what history can teach us. A window is something that opens and shuts. So the clear implication of everyone talking about a ‘public market window’ in the
- [Over the Hill and (still) far away for UK biotech companies](https://ucltf.co.uk/over-the-hill-and-still-far-away-for-uk-biotech-companies/) - By Simon Goldman (pictured), Investment Director, UCL Technology Fund – This month’s Lord Hill review will do little to halt UK biotech companies’ exodus to public markets across the pond. The review seeks to ease the path to a London Stock Exchange listing and thus increase growing businesses’ access to UK capital markets. ‘Going public’
- [On not downclimbing: the state of the biotech market](https://ucltf.co.uk/on-not-downclimbing-the-state-of-the-biotech-market/) - UCLTF's Investment Director, Simon Goldman, looks at the state of the biotech market. As someone who spends an unreasonable amount of time rock climbing, I know that ‘down-climbing’ (i.e. reversing an untenable position into which one has got one’s self) is a difficult but enormously important skill. It’s also important to know when to keep going.
- [UCLTF invests in Carbon Re, a spinout helping energy-intensive industries reach Net Zero](https://ucltf.co.uk/ucltf-invests-in-carbon-re/) - Carbon Re, a spinout from UCL and Cambridge University, has secured £1m of funding to progress its AI technology which helps energy-intensive industries operate more efficiently, and reach Net Zero targets. The £1m investment has been secured from the Clean Growth Fund, alongside UCL Technology Fund (managed by Albion VC in collaboration with UCL Business Ltd),
- [Phasecraft improves Hamiltonian simulation algorithms for near-term quantum hardware](https://ucltf.co.uk/phasecraft-improves-hamiltonian-simulation-algorithms-for-near-term-quantum-hardware/) - Phasecraft reveal their latest research in which they work one layer below the standard quantum circuit model to achieve a speedup of up to 5 orders of magnitude for quantum simulation of materials models. The quantum circuit model is the de-facto way of designing quantum algorithms. Yet any level of abstraction away from the underlying
- [UCLTF Showcase 2021 - The Highlights](https://ucltf.co.uk/ucltf-showcase-2021-the-highlights/)
- [UCL, Imperial College London and University of Cambridge are behind innovative industry university collaboration receiving £100m funding to rapidly advance cutting-edge science](https://ucltf.co.uk/ucl-imperial-college-london-and-university-of-cambridge-are-behind-innovative-industry-university-collaboration-receiving-100m-funding/) - Apollo Therapeutics, a unique collaboration between three leading universities (University College London, Imperial College and University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Johnson & Johnson) set up in late 2015 has received £100m in investment to further develop and translate early-stage science into clinical development for patient benefit. In order to
- [NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma](https://ucltf.co.uk/novalgen-doses-first-patient-in-phase-i-study-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/) - – NVG-111 is the first-in-class T-cell engager that simultaneously binds CD3 on T-cell and ROR1 on tumor cells – London, United Kingdom, June 9, 2021 – NovalGen Ltd (“NovalGen”), a clinical stage biopharmaceutical company developing breakthrough cancer therapies today announced that it has dosed the first patient in a Phase I/2 open-label study of a first-in-class
- [NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma](https://ucltf.co.uk/novalgen-presents-data-at-american-society-of-clinical-oncology-for-novel-ror1xcd3-bispecific-antibody-for-non-hodgkin-lymphoma/) - London, United Kingdom, May 20, 2021 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announced the company will give a poster presentation at the American Society of Clinical Oncology (“ASCO”) Annual meeting 2021, taking place June 4-8, 2021. NovalGen has developed an ROR1xCD3 bispecific antibody T cell engager, NVG-111, that is currently
- [Platform technologies: going deep to go wide](https://ucltf.co.uk/platform-technologies-going-deep-to-go-wide/) - Biomedical platform technologies are appealing because they can create impact (and therefore revenues) in multiple markets or indications, with less investment needed to get there. The commonalities between products arising from a platform, such as a shared manufacturing process, result in scalability. Venture capitalists adore this because it increases the chances of realising a much
- [UCL Technology Fund secures partnership with Viralgen, leading gene therapy manufacturer](https://ucltf.co.uk/ucltf-secures-partnership-with-viralgen/) - The UCL Technology Fund and Viralgen Vector Core, a Spanish CDMO offering best-in-class manufacturing for gene therapy, have entered into a partnership agreement to support commercialisation of early-stage research from UCL. Viralgen, created in 2017 in response to the unmet need for manufacturing of gene therapies, specialises in the production of recombinant adeno-associated viral (rAAV)
- [NovalGen receives CTA approval to start a Phase 1/2 first in human study](https://ucltf.co.uk/novalgen-receives-cta-approval-to-start-phase-1-2-first-in-human-study/) - NovalGen receives CTA approval to start a Phase 1/2 first in human study. London, United Kingdom, 7 April 2021 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announced that its Clinical Trial Application (“CTA”) has been accepted by the UK Medicines and Healthcare products Regulatory Agency (“MHRA”), and that University College London Hospital
- [Achilles Therapeutics Announces Pricing of Initial Public Offering](https://ucltf.co.uk/achilles-tx-announces-pricing-of-initial-public-offering/) - London, UK 30 March 2021 – Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares at an initial public offering price of $18.00 per ADS
- [Intrinsic closes £1.35m seed funding round to prototype next generation memory devices](https://ucltf.co.uk/intrinsic-closes-1-35m-seed-funding-round-to-prototype-next-generation-memory-devices/) - Memory innovator Intrinsic Semiconductor Technologies Ltd (“Intrinsic”) has announced the close of a £1.35m seed funding round led by investors UCL Technology Fund and IP Group plc. The funding will enable Intrinsic to disrupt the $60bn non-volatile memory market by partnering with leading semiconductor research foundry, imec in Belgium, to develop prototypes of its proprietary
- [Want to build a deeptech startup? Throw out the VC playbook](https://ucltf.co.uk/want-to-build-a-deeptech-startup-throw-out-the-vc-playbook/) - Every startup founder needs a good dose of grit, stamina and endurance to take a startup from idea to the heights of unicorn status. But deeptech entrepreneurs need to dig particularly deeply into their own resources to create something exceptional. Building a startup isn’t easy. Despite the vast number of business births each year, business
- [International Women’s Day 2021 – Meet Leigh Brody, UCLTF Investment Manager](https://ucltf.co.uk/international-womens-day-2021-meet-leigh-brody-ucltf-investment-manager/) - To celebrate International Women's Day, we interviewed Leigh Brody, UCLTF Investment Manager. Leigh Brody joined the UCL Technology Fund in January 2021, after ten years of experience in the life sciences. Having started as a bench scientist at the Broad Institute, she went on to do a PhD in Biomedical Sciences, which led her into
- [Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies](https://ucltf.co.uk/philip-beales-launches-axovia-tx-to-develop-transformative-medicines-for-ciliopathies/) - Axovia, an innovative gene therapy company developing disease-transformative medicines for ciliopathies, is a majority-owned subsidiary of Jaguar Gene Therapy, which is backed by Deerfield Management and UCL Technology Fund. Axovia Therapeutics, an innovative gene therapy company developing disease-transformative medicines for ciliopathies, led by renowned researcher Professor Philip Beales, launched today after being in stealth mode
- [NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials](https://ucltf.co.uk/novalgen-enters-strategic-partnership-with-halix-b-v-to-manufacture-clinical-trial-materials/) - London, United Kingdom and Leiden, The Netherlands, February 22nd 2021 – NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies and HALIX B.V. (“HALIX”), a contract development and manufacturing organisation, today announced a strategic partnership. Within the scope of this partnership, HALIX will provide manufacturing of clinical supply of NovalGen’s therapies. NovalGen’s innovative platform
- [Why you should consider manufacturing from the start of the biotech R&D process](https://ucltf.co.uk/why-you-should-consider-manufacturing-from-the-start-of-the-biotech-r-and-d-process/) - Simon Goldman, February 2021 - One of the most important, yet under-appreciated aspects of biotech commercialisation is the challenge of manufacturing your product at scale. This gained global prominence in the last month as the promise of coronavirus vaccines smashed into the reality of manufacturing bottlenecks and problems with scale-up. This jarring reality-check demonstrated that
- [Quell Therapeutics Expands Series A Financing to $84m](https://ucltf.co.uk/quell-tx-expands-series-a-financing-to-84m/) - Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd, who have committed an additional $34.7 million and UCL Technology Fund who have committed an additional $1 million; bringing the total Series A financing
- [UCL Technology Fund talks to the PanAngium team](https://ucltf.co.uk/ucltf-talks-to-the-panangium-team/) - UCL Technology Fund's Simon Goldman talks to Academic Co-Founders of PanAngium, Professors Steve Moss and John Greenwood.
- [Phasecraft announces largest seed funding round for a UK quantum computing company and new technology breakthroughs](https://ucltf.co.uk/phasecraft-announces-largest-seed-funding-round-for-a-uk-quantum-computing-company-and-new-technology-breakthroughs/) - On the back of new quantum algorithm breakthroughs, Phasecraft has today closed a record seed round for a quantum computing company in the UK. Its new £3.7m seed funding round is led by VC firm LocalGlobe with Episode1 along with previous investors. Phasecraft previously raised a £750,000 pre-seed round led by UCL Technology Fund with Parkwalk Advisors
- [UCL Technology Fund talks to co-founders of Echopoint about all things startups, fundraising and VC](https://ucltf.co.uk/ucltf-talks-to-co-founders-of-echopoint/) - David Grimm, Director at the UCL Technology Fund talks to co-founders of Echopoint Malcolm Finlay and Adrien Desjardins.
- [Echopoint raises £2.8m to address the ‘grey zone’ of heart disease treatment](https://ucltf.co.uk/echopoint-raises-2-8m-to-address-grey-zone-of-heart-disease-treatment/) - Echopoint Medical Ltd, a spinout company from UCL, has raised £2.8m to develop optical sensing technology to help heart disease patients in a grey zone where the need for treatment is unclear. Coronary heart disease is a major cause of death worldwide and more than 7 million* people have a diagnosis in the UK alone.
- [Third Space Learning raises £4.3m Series-A extension and announces a commercial partnership with China’s NetDragon to accelerate plans for international expansion](https://ucltf.co.uk/third-space-learning-raises-4-3m-series-a-extension-and-announces-commercial-partnership-with-netdragon/) - Third Space Learning (TSL), the UK’s leading online tutoring company, has completed a £4.3m funding extension from existing investors, Ananda, Downing Ventures, NESTA and the UCL Technology Fund. The recent investment was made over two stages to support development since the Series-A funding round which initially closed in 2017. The company has now raised a
- [Nozzle.ai raises $2.6m to accelerate adoption of AI platform with brands and sellers on Amazon](https://ucltf.co.uk/nozzle-raises-2-6m-to-accelerate-adoption-of-ai-platform-with-brands-and-sellers-on-amazon/) - Nozzle.ai, an eCommerce and advertising optimisation platform for Amazon, has raised $2.6 million (£2 million) in funding from Parkwalk Advisors, The Angel CoFund (ACF), UCL Technology Fund (UCLTF), and a syndicate of eCommerce-expert angel investors. The funding will accelerate the company’s growth as it attracts major international brands and agencies to its proprietary AI platform.
- [UCL Technology Fund and Orchard Therapeutics: from idea to Nasdaq IPO and beyond](https://ucltf.co.uk/ucltf-and-orchard-tx-from-idea-to-nasdaq-ipo-and-beyond/) - Dr Simon Goldman, interviews CEO of Orchard Therapeutics, Professor Bobby Gaspar.
- [We are recruiting a Life Sciences Investor for the UCL Technology Fund](https://ucltf.co.uk/we-are-recruiting-a-life-sciences-investor-for-ucltf/) - We are recruiting a new Investment Manager to join the Life Sciences team within UCL Technology Fund. At AlbionVC we are building the future of enterprise and healthcare. With around £500m of venture capital funds under management, our experienced team has been investing at the cutting edge of technology and science for over 20 years
- [UCL engineering cancer antibody therapies for Covid-19](https://ucltf.co.uk/ucl-engineering-cancer-antibody-therapies-for-covid-19/) - UCL’s Cancer Institute is repurposing a sophisticated antibody engineering approach, funded by the UCL Technology Fund (UCLTF), to research and develop a new treatment against Covid-19. A new project, led by Dr Martin Pule, Senior Lecturer in Haematology and Professor Kerry Chester, Department of Oncology, will investigate pivoting existing research used in the fight against
- [Why we Invested in Quantum Computing start-up Phasecraft](https://ucltf.co.uk/why-we-invested-in-quantum-computing-start-up-phasecraft/) - There has been a leap in excitement about quantum computing in the last year thanks to the emergence of a new class of quantum computers. Noisy Intermediate-Scale Quantum (NISQ) machines are being developed by tech giants and well-funded startups and, for the first-time, quantum computers solving useful problems could become a reality. From an investor’s
- [Orchard Therapeutics Announces Update from POC Study of OTL-203](https://ucltf.co.uk/orchard-therapeutics-announces-update-from-poc-study-of-otl-203/) - Orchard Therapeutics announced data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, a gene therapy for the treatment of mucopolysaccharidosis type I (MPS-I) developed at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan. The results presented in an oral presentation at the Society for the Study of Inborn
- [UCL Technology Fund Showcase 2019](https://ucltf.co.uk/ucltf-showcase-2019/) - We would like to thank everyone who attended the 2019 UCL Technology Fund showcase. We hope the event provided some insight on how the Fund supports innovation coming out of UCL. We would also like to thank our wonderful guest speakers for taking the time to showcase their innovation. Save the Date! We are delighted
- [Fund leads £750k investment in Phasecraft](https://ucltf.co.uk/fund-leads-750k-investment-in-phasecraft/) - The UCL Technology Fund led a £750k investment into Phasecraft, a pioneering quantum computing company, along with co-investors Parkwalk Advisors and the London Co-Investment Fund. Phasecraft, cofounded by academics at UCL and the University of Bristol, is developing software for quantum computers using some of the best talent in the sector, and aims to solve
- [Data Supports Achievement of Proof-of-Concept Milestone for OTL-300](https://ucltf.co.uk/data-supports-achievement-of-proof-of-concept-milestone-for-otl-300/) - Orchard Therapeutics has announced the achievement of clinical proof-of-concept based on data from the trial of OTL-300, for the treatment of transfusion-dependent beta-thalassemia (TDT). The primary endpoint of transfusion reduction was achieved after one year of follow-up in eight out of nine TDT patients treated with OTL-300. All nine patients met the safety endpoints with
- [Albion to Manage the UCL Technology Fund](https://ucltf.co.uk/albion-to-manage-ucltf/) - Albion Capital, one of the largest independent venture capital investors in the UK is to manage and administer the newly launched UCL Technology Fund, (“the Fund”), which has raised £50 million to commercialise University College London’s (“UCL”) world-class research output. Albion Capital will manage and administer the Fund in partnership with UCL’s technology transfer company UCL Business,
- [Orchard Therapeutics launches with £21m series A funding round](https://ucltf.co.uk/orchard-tx-launches-with-21-m-series-a-funding-round/) - Orchard Therapeutics has secured £21 million in Series A financing led by F-Prime with UCLTF. Orchard Therapeutics is a biotechnology company that will develop transformative gene therapies for life threatening orphan diseases. As part of its launch, Orchard Therapeutics' has announced formal partnerships with UCL, Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”),
- [UCLTF fund drug development platform Canbex for the treatment of multiple sclerosis](https://ucltf.co.uk/ucltf-fund-canbex-for-the-treatment-of-multiple-sclerosis/) - Canbex was established to develop the VSN compound series, a drug development platform with potential applications in a wide range of therapeutic areas due to its mechanism of action. The lead molecule of the series, VSN16R, is in a Phase II trial for the treatment of spasticity in people with multiple sclerosis.
- [UCL Technology Fund has approved investment of up to £1m in the development of a gene therapy for p47-CGD](https://ucltf.co.uk/ucltf-approved-investment-of-up-to-1m-in-development-of-gene-therapy-for-p47-cgd/) - The UCL Technology Fund has approved an investment of up to £1m to support the development of a gene therapy for p47phox-deficient chronic granulomatous disease (p47-CGD) through to a clinical trial in which it could potentially cure patients completely of this devastating disease. p47-CGD is a rare genetic disorder in which the ability of immune
- [UCL Technology Fund and ParkWalk invest in adtech machine learning company MediaGamma](https://ucltf.co.uk/ucltf-and-parkwalk-invest-in-mediagamma/) - The UCL Technology Fund has invested in MediaGamma, the predictive analytics software company, as part of a £2m round in partnership with ParkWalk Advisors and the London Co-Investment Fund (LCIF). MediaGamma has developed a world leading enterprise-grade reinforcement machine learning (self-learning) platform, delivering decisions in under five milliseconds. It has proven its technology in programmatic
- [UCL Technology Fund invests in cell therapy company Glialign](https://ucltf.co.uk/ucltf-invests-in-glialign/) - The UCL Technology Fund, UK Innovation & Science Seed Fund, alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd, which is developing a novel cell therapy for peripheral nerve repair. Hundreds of thousands of people every year are affected by severe peripheral nerve damage, resulting in paralysis and loss of sensation,
- [UCL Technology Fund Showcase 2018](https://ucltf.co.uk/ucl-technology-fund-showcase-2018/) - The inaugural UCL Technology Fund Showcase, held at Digital Catapult, brought together two years of investing in world-leading and world-changing UCL technologies and innovations. Despite the tempting sunshine outside, the event was oversubscribed and there was standing room only in the auditorium. The aim of the event was to showcase just a small selection of
- [Freeline secures over £88m of funding](https://ucltf.co.uk/freeline-secures-over-88-m-of-funding/) - Freeline Therapeutics announces today that it has raised over £88 million of new capital in a Series B financing round. Freeline Therapeutics is a clinical stage company focused on treatment of chronic systemic diseases with liver targeted adeno-associated virus (AAV) gene therapy, announces today that it has raised over £88 million of new capital in
- [Matr raises £4.75m for AI teaching platform](https://ucltf.co.uk/matr-raises-4-75m-for-ai-teaching-platform/) - Matr, the online teaching platform, has announced it has closed a £4.75 million Series A investment round led by the UCL Technology Fund, the company has now raised £8.25 million in funding. Following an initial focus on providing online teaching to support children in UK schools, via the company’s Third Space Learning brand, the new
- [Bloomsbury AI joins the Facebook Team in London](https://ucltf.co.uk/bloomsbury-ai-joins-the-facebook-team-in-london/) - UCL Technology Fund is very proud to have backed Bloomsbury AI and we are delighted that they are joining the Facebook team.
- [UCL Technology Fund investment MeiraGTx raises $75m at IPO](https://ucltf.co.uk/ucltf-investment-meiragtx-raises-75m-at-ipo/) - MeiraGTx is its first UCLTF investment to IPO. UCL Technology Fund investment MeiraGTx Holdings plc (‘MeiraGTx’), the clinical stage gene therapy company, has raised $75million at IPO, pricing five million shares at $15.00 per share on the Nasdaq Global Select Market on June 12 2018. MeiraGTx has strong roots in UCL; its rare eye diseases
- [UCL spinout Hazy adds $1.8m in seed funding](https://ucltf.co.uk/ucl-spinout-hazy-adds-1-8m-in-seed-funding/) - Hazy, the London-based AI company enabling ethical, effortless and GDPR-compliant data sharing for responsible businesses, has announced an additional $1.8 million seed funding led by UCL Technology Fund, alongside Nationwide Building Society, Pentland, Amadeus Capital Partners, AI Seed and other investors. This takes Hazy’s total seed funding to $2.8 million following a $1 million investment
- [Orchard Therapeutics announces closing of $225m Initial Public Offering](https://ucltf.co.uk/orchard-tx-announces-closing-of-225m-initial-public-offering/) - Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has today announced closing of its initial public offering. This initial public offering of 16,103,572 American Depositary Shares (“ADSs”), each represents an ordinary share at an initial public offering price of $14.00 per share. The gross
- [IGEM Therapeutics Announces Final Close of £5m Series A Financing Round](https://ucltf.co.uk/igem-tx-announces-final-close-of-5m-series-a-financing-round/) - New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel IgE-based platform technology. IGEM Therapeutics (IGEM or “the Company”), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured an additional £3 million to close
- [Hazy included in Forbes '15 Machine Learning Companies To Watch In Europe'](https://ucltf.co.uk/hazy-in-forbes-15-machine-learning-companies-to-watch-in-europe/) - Hazy has been listed by Forbes as one of the Top 15 European Machine Learning companies to watch. Hazy is an AI spin-out from UCL and is one of the businesses invested in by the UCL Technology Fund which is managed by Albion in collaboration with UCLB. Contacts www.hazy.com
- [Orchard Therapeutics achieves 100% survival rate during trial treatment for ADA-SCID](https://ucltf.co.uk/orchard-tx-achieves-100-survival-rate-during-trial-treatment-for-ada-scid/) - Orchard Therapeutics, a commercial-stage biopharmaceutical company, presented their two-year follow-up data in 20 patients from the registrational trial evaluating OTL-101, aimed at treating those with adenosine deaminase deficiency (ADA-SCID). They achieved a 100% Overall Survival and 100% Event Free Survival in Patients Treated with OTL-101; compared to 88% OS and 56% EvFS with Historical HSCT
- [Portfolio company Astroscreen featured in the Evening Standard](https://ucltf.co.uk/portfolio-company-astroscreen-featured-in-evening-standard/) - As the UK gears up for a potential election, there are concerns over the role disinformation will play in democracy. Ali Tehrani, CEO of Astroscreen, says creating the tools to fight disinformation online is the new arms race. You can read the full article on the Evening Standard website.
- [Astroscreen raises $1m to detect social media manipulation](https://ucltf.co.uk/astroscreen-raises-1m-to-detect-social-media-manipulation/) - UK-based start-up Astroscreen has secured $1M in initial funding to progress its pioneering technology which identifies carriers of disinformation on social media. Techniques include coordinated activity detection, linguistic fingerprinting and fake account and botnet detection. The funding round was led by Speedinvest, UCL Technology Fund, which is managed by AlbionVC in collaboration with UCLB, Luminous
- [UCLTF nominated for 'Investment Unit of the Year'](https://ucltf.co.uk/ucltf-nominated-for-investment-unit-of-the-year/) - We are delighted to announce that the UCL Technology Fund has been nominated for Investment Unit of the Year by Global University Venturing (GUV). The winners will be revealed at the gala dinner on May 22 as part of our GUV: Fusion conference, run jointly with the GCV Symposium, in London. Find out more about GUV,
- [Odin Vision scales up its cancer detection technology](https://ucltf.co.uk/odin-vision-scales-up-its-cancer-detection-technology/) - Innovative medtech company Odin Vision is to scale up its pioneering cancer detection technology thanks to an investment round led by the UCL Technology Fund alongside London Co-Investment Fund (LCIF) and AI seed and grant funding from InnovateUK, the NHS and the UK Space Agency and European Space Agency. The company, led by Peter Mountney
- [UCLTF completes £1m investment into Quell Therapeutics as part of £35m Series A round](https://ucltf.co.uk/ucltf-completes-1m-investment-into-quell-therapeutics-as-part-of-35m-series-a-round/) - UCLTF £1m investment into Quell Therapeutics is part of a £35m Series A round led by Syncona. Syncona announces the foundation of Quell Therapeutics, a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed £34 million with a further £1 million being contributed by UCL
- [Hazy wins 'Best Innovation in Data Protection & Privacy'](https://ucltf.co.uk/hazy-wins-best-innovation-in-data-protection-amp-privacy/) - Hazy wins 'Best Innovation in Data Protection & Privacy' at the 2019 CogX awards. A huge congratulations to the team at Hazy for winning the 'Best Innovation in Data Protection & Privacy' at the 2019 CogX awards. CogX is the world’s leading AI festival with over 15,000 people in attendance from the highest levels of
- [Andrew Elder on healthtech investing](https://ucltf.co.uk/andrew-elder-on-healthtech-investing/) - Andrew Elder talks to HS. about his journey from brain surgeon to venture capitalist, the history of healthtech investing and how he chooses his investment companies. You can listen to the full podcast here.
- [2019 Brochure](https://ucltf.co.uk/2019-brochure/) - Featuring fund highlights from the past year. The UCL Technology Fund provides both financial and direct, hands-on support for the commercialisation of UCL’s world-class research, focusing in particular on the physical and life sciences. Click here to download the UCL Technology Fund 2019 Brochure.
- [UCL’s Centre for Amyloidosis and Acute Phase Proteins published in the Journal of Medicinal Chemistry](https://ucltf.co.uk/ucls-centre-for-amyloidosis-and-acute-phase-proteins-published-in-journal-of-medicinal-chemistry/) - Ground-breaking work by Prof Alessandra Corazza, Prof Sir Mark Pepys, Prof Vittorio Bellotti and colleagues of the Wolfson Drug Discovery Unit at UCL’s Centre for Amyloidosis and Acute Phase Proteins and funded by the UCL Technology Fund was published today in the Journal of Medicinal Chemistry. Stabilisation of the circulating protein transthyretin is a key
- [Achilles Therapeutics raises £100m in Series B](https://ucltf.co.uk/achilles-therapeutics-raises-100m-in-series-b/) - Achilles Therapeutics (“Achilles”), a bio-pharmaceutical company developing personalised cancer immunotherapies, today announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. Proceeds from this financing will deliver two
- [Quell Therapeutics makes FierceBiotech's 2019 Fierce 15](https://ucltf.co.uk/quell-therapeutics-makes-fiercebiotechs-2019-fierce-15/) - The list highlights biotech companies whose hard work and cutting-edge research aims to stop disease in its tracks. Formed earlier this year, UCLTF portfolio company, Quell Thereapeutics was established with the aim of developing engineered T regulatory (Treg) cell therapies. Bringing together leaders in this field of expertise, Quell will seek to utilise the power
- [AstronauTx secures UCLTF investment for dementia therapeutics](https://ucltf.co.uk/astronautx-secures-ucltf-investment-for-dementia-therapeutics/) - AstronauTx Ltd, a biotech company developing new medicines designed to restore the normal behaviour of astrocytes for the treatment of Alzheimer’s disease and other neurodegenerative diseases, today announces £1 million investment from the UCL Technology Fund to enable the development of translatable biomarkers for their drug discovery programs. We’re delighted to be supporting the world-leading
- [Epsilogen Announces £3m Series A2 financing and licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London](https://ucltf.co.uk/epsilogen-announces-3m-series-a2-financing-and-licences-mov18/) - Epsilogen Ltd (formerly known as IGEM Therapeutics), a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has closed a £3m A2 financing round from existing investors Epidarex Capital, Alsa Holdings and UCL Technology Fund (UCLTF). Epsilogen has also announced that it has in-licenced exclusive global rights
- [UCL Technology Fund announces first close of £100m Fund 2](https://ucltf.co.uk/ucltf-announces-first-close-of-100m-fund-2/) - UCL Technology Fund (UCLTF), managed by AlbionVC in collaboration with UCL Business (UCLB) (the university’s commercialisation company and part of UCL Innovation & Enterprise), announces first close of a £100m target Fund 2. The new fund will continue to support UCL in achieving the full potential of innovations that have prospects for outstanding societal impact
- [Humanloop raises funding to teach AI to learn from humans faster](https://ucltf.co.uk/humanloop-raises-funding-to-teach-ai-to-learn-from-humans-faster/) - Humanloop, a game changing UCL spinout, has attracted investment from UCL’s Technology Fund (UCLTF). Based on the world-leading research of two notable academics at UCL’s AI Centre Humanloop is teaching AI to improve performance with 10 times less human training than existing systems. The UCLTF has invested in Humanloop to help the team, which includes
- [An evolution in early stage gene therapy funding models](https://ucltf.co.uk/an-evolution-in-early-stage-gene-therapy-funding-models/) - A tsunami of curative gene therapies for rare diseases will get through pivotal trials in the coming year or two. This comes on the back of substantial venture-capital finance which has brought these programs out of gestation in academic labs and into the real world. Those in the clinic today are predominantly gene therapy programs
- [Freeline Therapeutics makes its NASDAQ debut](https://ucltf.co.uk/freeline-therapeutics-makes-nasdaq-debut/) - Freeline Therapeutics Holdings plc (“Freeline”), a UCL Technology Fund portfolio company, has made its debut on NASDAQ in the United States. Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. It announced the pricing of its
- [Funding academic innovations in advanced therapies: an interview with Simon Goldman](https://ucltf.co.uk/funding-academic-innovations-in-advanced-therapies-an-interview-with-simon-goldman/) - Simon Goldman, Investment Manager for UCLTF, talks to RegMedNet about funding academic innovation.
- [Bramble energy secures significant new capital to accelerate its unique fuel cell deployment](https://ucltf.co.uk/bramble-energy-secures-new-capital-to-accelerate-its-unique-fuel-cell-deployment/) - Bramble Energy, the world’s most scalable hydrogen fuel cell company has raised a £5m Series A round. BGF led the round and was joined by existing investors including IP Group, Parkwalk Advisors, and UCL Technology Fund. Bramble Energy has developed the only technology capable of producing gigawatts of hydrogen fuel cells using existing global manufacturing

## Pages

- [Homepage](https://ucltf.co.uk/)
- [About Us](https://ucltf.co.uk/about-us/)
- [Disclaimer](https://ucltf.co.uk/disclaimer/)
- [Cookie Policy](https://ucltf.co.uk/cookie-policy/)
- [Privacy Notice](https://ucltf.co.uk/privacy-notice/)
- [Portfolio](https://ucltf.co.uk/portfolio/)
- [Contact](https://ucltf.co.uk/contact/)
- [The Team](https://ucltf.co.uk/the-team/)
- [News](https://ucltf.co.uk/news/)

## Team

- [Takashi Takenoshita](https://ucltf.co.uk/team/takashi-takenoshita/)
- [Dr Peter Loudon](https://ucltf.co.uk/team/dr-peter-loudon/)
- [Stefanos Theoharis](https://ucltf.co.uk/team/stefanos-theoharis/)
- [Sebastian Hunte](https://ucltf.co.uk/team/sebastian-hunte/)
- [David Grimm](https://ucltf.co.uk/team/david-grimm/)
- [Simon Goldman](https://ucltf.co.uk/team/simon-goldman/)
- [Leigh Brody](https://ucltf.co.uk/team/leigh-brody/)
- [Tanel Ozdemir](https://ucltf.co.uk/team/tanel-ozdemir/)
- [Andrew Elder](https://ucltf.co.uk/team/andrew-elder/)
- [Anne Lane](https://ucltf.co.uk/team/anne-lane/)
- [Ed Lascelles](https://ucltf.co.uk/team/ed-lascelles/)
- [Christoph Ruedig](https://ucltf.co.uk/team/christoph-ruedig/)
- [Richard Fagan](https://ucltf.co.uk/team/richard-fagan/)

## Portfolio

- [Hazy](https://ucltf.co.uk/portfolio/hazy/)
- [AstronauTx](https://ucltf.co.uk/portfolio/astronautx/)
- [EpilepsyGTx](https://ucltf.co.uk/portfolio/epilepsy-gtx/)
- [GQ Targeting](https://ucltf.co.uk/portfolio/gq-targeting/)
- [NovalGen](https://ucltf.co.uk/portfolio/novalgen/)
- [Pometry](https://ucltf.co.uk/portfolio/pometry/)
- [Oriole Networks](https://ucltf.co.uk/portfolio/oriole-networks/)
- [Phasecraft](https://ucltf.co.uk/portfolio/phasecraft/)
- [Intrinsic Semiconductor Technologies](https://ucltf.co.uk/portfolio/intrinsic-semiconductor-technologies/)
- [Echopoint Medical](https://ucltf.co.uk/portfolio/echopoint/)
- [Gaussion](https://ucltf.co.uk/portfolio/gaussion/)
- [Bloomsbury AI](https://ucltf.co.uk/portfolio/bloomsbury-ai/)
- [Spur Therapeutics](https://ucltf.co.uk/portfolio/freeline-therapeutics/)
- [Stanhope AI](https://ucltf.co.uk/portfolio/stanhope-ai/)
- [Glialign](https://ucltf.co.uk/portfolio/glialign/)
- [SenyaTx](https://ucltf.co.uk/portfolio/senya-tx/)
- [Cell therapy for glaucoma](https://ucltf.co.uk/portfolio/cell-therapy-for-glaucoma/)
- [ATTR](https://ucltf.co.uk/portfolio/apollo-therapeutics-limited/)
- [OPS-γδ](https://ucltf.co.uk/portfolio/ops-γδ/)
- [Horizontal Cells Gene Therapy](https://ucltf.co.uk/portfolio/horizontal-cells-gene-therapy/)
- [Epsilogen](https://ucltf.co.uk/portfolio/epsilogen/)
- [Quell Therapeutics](https://ucltf.co.uk/portfolio/quell-therapeutics/)
- [Orchard Therapeutics](https://ucltf.co.uk/portfolio/orchard-therapeutics/)
- [Humanloop](https://ucltf.co.uk/portfolio/humanloop/)
- [KIT-AR](https://ucltf.co.uk/portfolio/kit-ar/)
- [Third Space Learning](https://ucltf.co.uk/portfolio/third-space-learning/)
- [Odin Vision](https://ucltf.co.uk/portfolio/odin-vision/)
- [Carbon Re](https://ucltf.co.uk/portfolio/carbon-re/)
- [Bloomsbury Genetic Therapies](https://ucltf.co.uk/portfolio/bloomsbury-genetic-therapies/)
- [Apollo Therapeutics Limited](https://ucltf.co.uk/portfolio/achilles-therapeutics/)
- [Bramble Energy](https://ucltf.co.uk/portfolio/bramble-energy/)
- [MeiraGTx](https://ucltf.co.uk/portfolio/meira-gtx/)

## Categories

- [Insights](https://ucltf.co.uk/news/insights/)
- [Investments](https://ucltf.co.uk/news/investments/)
- [News](https://ucltf.co.uk/news/news/)
- [Web](https://ucltf.co.uk/news/web/)

## Tags

- [portfolio](https://ucltf.co.uk/tag/portfolio/)
- [Physical Sciences](https://ucltf.co.uk/tag/physical-sciences/)
- [Life Sciences](https://ucltf.co.uk/tag/life-sciences/)

## Sector

- [Investment team](https://ucltf.co.uk/sector/investment-team/)
- [Management team](https://ucltf.co.uk/sector/management-team/)
- [Venture Partners](https://ucltf.co.uk/sector/venture-partners/)

## portfolio-category

- [Life Sciences](https://ucltf.co.uk/category/life-sciences/)
- [Physical Sciences & Engineering](https://ucltf.co.uk/category/physical-sciences/)

## Investment types

- [PoC](https://ucltf.co.uk/portfolio-investment-type/poc/)
- [Licensing](https://ucltf.co.uk/portfolio-investment-type/licensing/)
- [Spin out](https://ucltf.co.uk/portfolio-investment-type/spin-out/)

## Stages

- [Early](https://ucltf.co.uk/portfolio-stage/early/)
- [Growth](https://ucltf.co.uk/portfolio-stage/growth/)
- [Exited](https://ucltf.co.uk/portfolio-stage/exited/)